| Literature DB >> 29500328 |
Ellen Heitzer1,2,3, Michael R Speicher4,2.
Abstract
<b/> In this issue of Cancer Discovery, Miyamoto and colleagues adapted their microfluidic CTC-iChip isolation platform with a digital RNA-PCR readout for eight prostate-specific transcripts and two assays for the androgen receptor mRNA splice variant ARV7 and the TMPRSS2-ERG translocation transcript. In patients with metastatic castrate-resistant prostate cancer at initiating abiraterone therapy in a first-line setting, the resulting RNA-based digital circulating tumor cell signatures identified patients with a shorter overall survival, and in patients with clinically localized disease, the signatures identified those with seminal vesicle invasion and pelvic lymph node involvement. Cancer Discov; 8(3); 269-71. ©2018 AACR.See related article by Miyamoto et al., p. 288. ©2018 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29500328 DOI: 10.1158/2159-8290.CD-18-0075
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397